Zydus Lifesciences Limited
ZYDUSLIFE
Κατάταξη σε μετοχές
#1743
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Τιμή μετοχής
$12.30
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$12.27B
Αλλαγή (1 ημέρα)
0.06%
Αλλαγή (1 έτος)
8.33%
Χώρα
IN
Εμπόριο Zydus Lifesciences Limited (ZYDUSLIFE)
Κατηγορία
Healthcare
Κέρδη για την Zydus Lifesciences Limited (ZYDUSLIFE)
Κέρδη τον Jun 2026 TTM: $674.03M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Zydus Lifesciences Limited, τα τρέχοντα κέρδη της εταιρείας είναι $674.03M. Το 2024, η εταιρεία παρουσίασε κέρδη $590.92M, αύξηση σε σχέση με των κερδών του 2023 που ήταν $326.63M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Zydus Lifesciences Limited από 2004 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $674.03M | -5.26% |
| 2025 | $711.42M | 20.39% |
| 2024 | $590.92M | 80.91% |
| 2023 | $326.63M | -14.04% |
| 2022 | $379.97M | 13.69% |
| 2021 | $334.22M | 65.19% |
| 2020 | $202.32M | -42.16% |
| 2019 | $349.80M | -4.85% |
| 2018 | $367.62M | 44.63% |
| 2017 | $254.19M | -21.37% |
| 2016 | $323.28M | 39.35% |
| 2015 | $231.99M | 47.59% |
| 2014 | $157.19M | 5.61% |
| 2013 | $148.84M | -4.97% |
| 2012 | $156.62M | -17.15% |
| 2011 | $189.05M | 40.60% |
| 2010 | $134.46M | 84.59% |
| 2009 | $72.84M | -9.87% |
| 2008 | $80.82M | 27.90% |
| 2007 | $63.19M | 59.18% |
| 2006 | $39.70M | 26.43% |
| 2005 | $31.40M | -10.04% |
| 2004 | $34.90M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 161.79% |
IN
|
